A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease

NCT07720635 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Eye Disease

Interventions

DRUG: KHN939
DRUG: Placebo

Sponsor

Beijing Kanghong Biological Medicine Co., Ltd.